• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides a process for the synthesis of penciclovir and famciclovir by 9-substituting 2-amino-6-chloropurine (ACP) with an appropriate side chain precursor, followed by conversion of the 6-chloro moiety to a hydroxy moiety (i.e. to form a guanine) or hydrogen (to form a 2-aminopurine), respectively.
    公开号:US20010004668A1
    申请号:US09/734,051
    申请日:2000-12-11
    公开日:2001-06-21
    发明作者:Graham Geen；Richard Jarvest
    申请人:Beecham Group PLC；
    IPC主号:C07D473-00
    专利说明:
    [0001] This is a continuation-in-part application of U.S. Ser. No. 08/132,082, filed Oct. 5, 1993 and U.S. Ser. No. 07/918,111 filed Jul. 20, 1992. [0001]
    [0002] The present invention relates to a process for the preparation of novel compounds which are of potential use as antiviral agents, to a process for their preparation and to their use as pharmaceuticals. [0002]
    [0003] U.S. Pat. Nos. 5075445 and 5246937, the subject matter of which is incorporated herein by reference, disclose antiviral compounds penciclovir (Example 4 of '445) and famciclovir (Example 2 of '937) and methods for their preparation. 2-Amino-6-chloropurine (ACP) is 9-substituted with an appropriate side chain precursor, followed by conversion of the 6-chloro moiety to a hydroxy moiety (i.e. to form a guanine) or hydrogen (a 2-aminopurine). [0003]
    [0004] In particular, beginning column 4 of '445, and column 3 of '937, a process is described for the preparation of such purine derivatives wherein the hydroxy groups in the 9-(4-hydroxy-3-hydroxymethylbut-1-yl) substituent are in acylated form, i.e. the ACP is reacted with 2-acyloxymethyl-4-(leaving group)-but-1-yl acylate. The leaving group may be halo, such as chloro, bromo or iodo although alternative leaving groups, such as tosylate or methanesulphonate may be employed. The acyl groups have advantages over the alternative protecting groups already described in acyclonucleoside chemistry in providing a good yield of 9-substitution and avoiding by-products which are difficult to isolate. [0004]
    [0005] The following examples illustrate the process of the invention to form 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine, (DACP). The following descriptions illustrate the preparation of side chain intermediates. Penciclovir is prepared from DACP according to the method described in '445 column 14, lines 4-16 and famciclovir is prepared from DACP according to the method described in Example 2 of '937. [0005] Example 1
    [0006] 2-Acetoxymethyl-4-bromobutyl acetate was reacted with ACP as described in Examples 11 and 10 of '445. [0006] Example 2
    [0007] A mixture of ACP (10.0 mmol), 2-acetoxymethyl-4-iodobutyl acetate (3.30 g, 10.5 mmol), and anhydrous potassium carbonate (2.07 g, 15.0 mmol) was stirred for 18 hours at ambient temperature in dry DMF (40 ml) under an atmosphere of dry nitrogen. The mixture was then filtered to remove insoluble material, which was washed well with DMF. The combined filtrates were evaporated under reduced pressure and the residue purified directly by column chromatography on silica gel (150 g), eluting with various dichloromethane-methanol mixtures. Fractions containing the first-eluting N-9 isomer, and the second-eluting N-7 isomer were separately combined, rigorously evaporated and weighed. The N-9:N-7 alkylated product ratio obtained from the isolated weights was checked by integration of the respective H-8 [0007] 1HNMR signals in the spectrum of the crude residue.
    [0008] 9-(4-Acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine and 7-(4-acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine [0008]
    [0009] Column eluant dichloromethane-methanol 25:1. [0009]
    [0010] 9-isomer, 75%, m.p. [0010] 134-136° (ethyl acetate-diethyl ether).
    [0011] [0011] 1HNMR: 1.80-2.05 (m 3H,CHCH2), 2.00 (s,6H,2×COCH3), 4.03 (d,4H,2×CH2O), 4.15 (t,2H,CH2N), 6.87 (brs,2H,NH2), 8.16 (s,1H,H-8). 13CNMR: 20.47 (2×CH3), 27.75 (CH2), 34.45 (CH), 40.88 (CH2N), 63.43 (2×CH2O), 123.43 (C-5), 143.07 (C-8), 149.34 (C-6), 154.02 (C-4), 159.68 (C-2), 170.27 (2×CO). U.V. λmax 223.5 (ε27.600), 248.5 (5,800), 310 (7,700). Found; C:47.14, H:4.97, N:19.69. C14H18N5O4Cl requires; C:47.26, H:5.10, N: 19.68%.
    [0012] 7-isomer, 15%, m.p. [0012] 159-161° (dec). (butanol).
    [0013] [0013] 1HNMR: 1.60-2.10 (m,3H,CHCH2), 2.00 (s,6H,2×COCH3), 4.00 (d,4H,2×CH2O), 4.34 (m,2H,CH2N), 6.56 (brs,2H,NH2), 8.33 (s,1H,H-8). 13CNMR: 20.41 (2×CH3), 29.80 (CH2), 34.51 (CH), 44.06 (CH2N), 63.46 (2×CH2O), 114.65 (C-5), 141.97 (C-6), 149.28 (C-8), 159.81 (C-2), 164.24 (C-4), 170.12 (2×CO). U.V. λmax 222.5 (ε23.600), 253.5sh (3,700), 323 (5,400) Found; C:47.31, H:5.17, N:19.88. C14H18N5O4Cl requires; C:47.26, H:5.10, N: 19.68%.
    [0014] 2-Acetoxymethyl-4-bromobutyl acetate was prepared as described in Examples 5-8 of '445. [0014]
    [0015] 2-Acetoxymethyl-4-iodobutyl acetate was prepared as follows: [0015]
    [0016] a) To a stirred solution of 2-(2-benzyloxyethyl)propane-1,3-diol (J. Org. Chem., 1981, 46, 3204) (10.0 g, 47.6 mmol), 4-dimethylaminopyridine (0.55 g, 4.5 mmol), and pyridine (12.3 ml, 0.15 mol) in dichloromethane (54 ml) at −10° C. was added dropwise acetic anhydride (13.2 ml, 0.14 mol) over 20 minutes. After completion of the addition, the reaction mixture was stirred for a further 1 hour at 0° C., then diluted with dichloromethane (100 ml) and washed with 2M hydrochloric acid (2×50 ml), saturated sodium bicarbonate solution (50 ml), and brine (50 ml), dried (MgSO[0016] 4), and evaporated to give 2-acetoxymethyl-4-benzyloxybutyl acetate as a light yellow oil (13.2 g, 94%). b.p. 160-165°/0.5 mm.
    [0017] [0017] 1HNMR: 1.62 (q,2H,CHCH2), 2.00 (s,6H,2×CH3), 2.15 (m,1H,CH), 3.51 (t,2H,CH2CH2O), 4.03 (m,4H,2×CH2O), 4.46 (s,2H,OCH2Ph), 7.33 (m,5H,Ph). 13CNMR: 20.31 (2×CH3), 27.93 (CHCH2), 34.40 (CH), 63.73 (2×CH2O), 67.22 (CH2CH2O), 71.99 (CH2Ph), 127.22, 127.30, 128.09, 138.54 (Ph), 170.13 (2×CO). Found; C:65.07, H:7.76. C16H22O5 requires; C:65.29, H:7.53%.
    [0018] b) A solution of 2-acetoxymethyl-4-benzyloxybutyl acetate (15.5 g, 52.7 mmol) in ethanol (200 ml) was hydrogenated for 18 hours at ambient temperature over 10% palladium-carbon (2 g). Filtration and evaporation afforded the corresponding alcohol (10.2 g) as a colourless oil. [0018]
    [0019] c) To a stirred solution of the above oil and triethylamine (10.4 ml, 74.8 mmol) in dichloromethane (100 ml) cooled to −5° C. was added a solution of methanesulphonyl chloride (4.6 ml, 59.5 mmol) in dichloromethane (30 ml) dropwise over 30 minutes. After completion of the addition, the reaction mixture was stirred for a further 1 hour at −5° C., then washed with 2M hydrochloric acid (2×100 ml), saturated sodium bicarbonate solution (100 ml), and brine (10 ml), dried (MgSO[0019] 4) and evaporated to afford the corresponding methanesulphonate (14.1 g) as a pale yellow oil.
    [0020] d) A mixture of the above oil and sodium iodide (15.0 g, 0.1 mol) was stirred under reflux for 2 hours in acetone (150 ml), then cooled, poured into water (300 ml), and extracted with diethyl ether (3×150 ml). The combined ether extracts were washed with [0020] 10% sodium metabisulphite solution (250 ml), and brine (250 ml), dried (MgSO4) and evaporated to give a pale oil. This was purified by flash column chromatography on silica, eluant hexane-diethyl ether 3:2 affording the title compound as a colourless oil (13.1 g, 79% from 2-acetoxymethyl-4-benzyloxybutyl acetate).
    [0021] [0021] 1NMR: 1.88 (q,2H,CH2), 2.02 (s,6H,2×CH3), 2.10 (m,1H,CH), 3.33 (t,2H,CH2I), 4.02 (d,4H,2×CH2O). 13CNMR: 5.01 (CH2I), 20.48 (2×CH3), 32.04 (CH2), 37.87 (CH), 62.86 (2×CH2O), 170.02 (2×CO). EI-MS. m/e: 314 (M+), 254 (M+-HOAc), 211 (M+-HOAcAc), 187 (M+-I). Found; C:34.56, H:4.99. CgH15O41 requires; C:34.42, H:4.81%.
    权利要求:
    Claims (6)
    [1" id="US-20010004668-A1-CLM-00001] 1. A process for the preparation of i) penciclovir or ii) famciclovir which process comprises the reaction of 2-amino-6-chloropurine with 2-acetoxymethyl-4-(leaving group)-but-1-yl acetate;
    to give 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine;
    and thereafter:
    i) hydrolysing to give penciclovir:
    or
    ii) reducing to give famciclovir.
    [2" id="US-20010004668-A1-CLM-00002] 2. A process according to
    claim 1 wherein the leaving group is halo.
    [3" id="US-20010004668-A1-CLM-00003] 3. A compound known as 9-(4-acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine.
    [4" id="US-20010004668-A1-CLM-00004] 4. A compound known as 2-acetoxymethyl-4-halo-but-1-yl acetate.
    [5" id="US-20010004668-A1-CLM-00005] 5. A compound according to
    claim 4 wherein halo is bromo.
    [6" id="US-20010004668-A1-CLM-00006] 6. A compound according to
    claim 4 wherein halo is iodo.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6388074B2|2002-05-14|Process for the preparation of purine derivatives
    US6573378B1|2003-06-03|Antiviral guanine derivatives
    KR100555970B1|2006-03-06|A process for preparing 2-amino-1,3-propandiol derivatives
    US5036071A|1991-07-30|Derivatives of purine
    JP2856773B2|1999-02-10|New method for producing compounds
    US6806375B2|2004-10-19|Process for the production of purine derivatives and intermediates therefor
    US4910307A|1990-03-20|Process for preparing purines
    US5565565A|1996-10-15|Preparation of N-9 substituted guanine compounds
    US4965270A|1990-10-23|Purine derivatives
    DK168213B1|1994-02-28|Alkoxymethyl ether and alkoxymethyl ester derivatives of glycerol and process for the preparation of 9- | guanine and ethers and esters thereof
    Cope et al.1956|The Detosylation of 1, 4: 3, 6-Dianhydrohexitol Ditosylates and Syntheses of 1, 4: 2, 5: 3, 6-Trianhydro-D-Mannitol
    EP0302644B1|1997-01-29|Purine compounds and their preparation
    US5220024A|1993-06-15|Process for the preparation of purine derivatives as antiviral agents
    EP0289992B1|1994-04-27|Process for preparing purine derivates
    DE69917765T2|2005-07-14|PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES
    US6043364A|2000-03-28|Regiospecific process for synthesis of acyclic nucleosides
    Harnden et al.1994|Synthesis, oral bioavailability and in vivo activity of acetal derivatives of the selective antiherpesvirus agent 9-| guanine |
    EP0806425B1|2001-08-29|An improved regiospecific process for synthesis of acyclic nucleosides
    US5567816A|1996-10-22|Preparation of acyclovir using 1,3 dioxolane
    US5175288A|1992-12-29|Process for preparing purine derivatives and intermediates thereof
    KR930010559B1|1993-10-28|1-hydroxyalkyl xanthines, process for their preparation
    US5166397A|1992-11-24|Process for producing optically active cyclobutylamines
    US5225590A|1993-07-06|Alkoxy methyl ether and alkoxy methyl ester derivatives
    KR100618232B1|2006-09-04|Method for the preparation of famciclovir
    FI68053B|1985-03-29|FRAMEWORK FOR FRAMEWORK OF BASIC SUBSTITUTES ALKYLTEOFYLLINDERIVAT
    同族专利:
    公开号 | 公开日
    US6187922B1|2001-02-13|
    US6388074B2|2002-05-14|
    US5886215A|1999-03-23|
    US5684153A|1997-11-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2004110343A2|2003-06-13|2004-12-23|Kyungdong Pharm. Co., Ltd.|2-amino-9-purines and preparing methods for 9-[4-acetoxy-3-but-1-yl]- 2- aminopurine using the same|
    WO2010126600A1|2009-05-01|2010-11-04|Anaspec, Inc.|Optimal fret pairs and related methods|GB1523865A|1974-09-02|1978-09-06|Wellcome Found|Purine compunds and salts thereof|
    US4146715A|1975-08-27|1979-03-27|Burroughs Wellcome Co.|2-amido-9-hypoxanthines|
    US4197406A|1978-05-12|1980-04-08|Hoffmann-La Roche Inc.|D-Homosteroids|
    IL64501A|1980-12-22|1985-07-31|Astra Laekemedel Ab|9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use|
    KR880002276B1|1981-08-11|1988-10-21|더 웰컴 화운데이션 리미티드|Process for preparation of anti viral compounds|
    US4451478A|1982-03-12|1984-05-29|Newport Pharmaceuticals International, Inc.|Imidazole compounds|
    SE8203856D0|1982-06-21|1982-06-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF GUANINE II|
    SE8203855D0|1982-06-21|1982-06-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF GUANINE I|
    EP0158847B1|1982-10-14|1988-04-20|The Wellcome Foundation Limited|Antiviral purine derivatives|
    US4609662A|1982-10-14|1986-09-02|Burroughs Wellcome Co.|Method for using purine derivatives|
    US4461757A|1983-02-23|1984-07-24|Ens Bio Logicals Inc.|Dimethylaminomethylenated anti-herpes compounds|
    US5684153A|1984-08-16|1997-11-04|Beecham Group Plc|Process for the preparation of purine derivatives|
    EP0141927B1|1983-08-18|1991-10-30|Beecham Group Plc|Antiviral guanine derivatives|
    IL73682A|1983-12-20|1991-08-16|Medivir Ab|Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation|
    DE3571810D1|1984-01-26|1989-08-31|Merck & Co Inc|Substituted butyl guanines and their utilization in antiviral compositions|
    US4845084A|1984-01-26|1989-07-04|Merck & Co., Inc.|Phosphate derivatives of substituted butyl guanines, antiviral compositions containing them, and methods of treating viral infections with them|
    US4579849A|1984-04-06|1986-04-01|Merck & Co., Inc.|N-alkylguanine acyclonucleosides as antiviral agents|
    SE8406538D0|1984-12-21|1984-12-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF PURINE|
    US5246937A|1985-09-18|1993-09-21|Beecham Group P.L.C.|Purine derivatives|
    GB8817270D0|1988-07-20|1988-08-24|Beecham Group Plc|Novel process|
    GB8817607D0|1988-07-23|1988-09-01|Beecham Group Plc|Novel process|
    GB8822236D0|1988-09-21|1988-10-26|Beecham Group Plc|Chemical process|
    GB8907173D0|1989-03-30|1989-05-10|Beecham Group Plc|Novel compounds|
    GB9210839D0|1992-05-21|1992-07-08|Smithkline Beecham Plc|Novel compounds|US5684153A|1984-08-16|1997-11-04|Beecham Group Plc|Process for the preparation of purine derivatives|
    GB9807116D0|1998-04-02|1998-06-03|Smithkline Beecham Plc|Novel process|
    DE69923338T2|1998-11-02|2006-04-06|Gilead Sciences, Inc., Foster City|COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS B INFECTIONS|
    US6407077B1|1998-11-05|2002-06-18|Emory University|β-L nucleosides for the treatment of HIV infection|
    AUPQ806700A0|2000-06-08|2000-07-06|Commonwealth Scientific And Industrial Research Organisation|Antiviral agents|
    AT383355T|2001-03-01|2008-01-15|Abbott Lab|POLYMORPH AND OTHER CRYSTALLINE FORMS OF TOGETHER FTC|
    KR100573859B1|2002-07-15|2006-04-25|경동제약 주식회사|A process for preparing 9-[4-acetoxy-3-acetoxymethylbut-1-yl]-2-aminopurine|
    AU2003268213A1|2002-08-26|2004-03-11|Teva Pharmaceutical Industries Ltd.|Crystalline solid famciclovir forms i, ii, iii and preparation thereof|
    US9021529B2|2004-07-15|2015-04-28|Microsoft Technology Licensing, Llc|Content recordation techniques|
    US8383637B2|2004-08-06|2013-02-26|Jansssen Pharmaceutica N.V.|2-amino-quinazoline derivatives useful as inhibitors of β-secretase |
    US8436006B2|2004-08-06|2013-05-07|Jansssen Pharmaceutica N.V.|2-amino-quinazoline derivatives useful as inhibitors of β-secretase |
    US8426429B2|2004-08-06|2013-04-23|Jansssen Pharmaceutica N.V.|2-amino-quinazoline derivatives useful as inhibitors of β-secretase |
    GB2426247A|2005-05-20|2006-11-22|Arrow Int Ltd|Methods of preparing purine derivatives such as famciclovir|
    US7932261B2|2006-02-06|2011-04-26|Janssen Pharmaceutica Nv|Macrocycle derivatives useful as inhibitors of β-secretase |
    WO2007092846A2|2006-02-06|2007-08-16|Janssen Pharmaceutica N.V.|2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE |
    US7868022B2|2006-02-06|2011-01-11|Janssen Pharmaceutica Nv|2-amino-quinoline derivatives useful as inhibitors of β-secretase |
    EP1852435A1|2006-04-12|2007-11-07|SOLMAG S.p.A.|A process for the manufacture of famciclovir using phase-transfer catalysts|
    US20100137592A1|2007-06-21|2010-06-03|Asif Parvez Sayyed|Process for preparing purine derivative|
    EP2238111B1|2008-01-28|2013-01-16|Janssen Pharmaceutica NV|6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-secretase |
    EP2240472B1|2008-01-29|2012-11-21|Janssen Pharmaceutica NV|2-amino-quinoline derivatives useful as inhibitors ofbeta-secretase |
    CN108484605B|2018-03-16|2020-08-21|上药康丽（常州）药业有限公司|Preparation method of 2-amino-6-chloro-9-purine|
    法律状态:
    2001-04-13| AS| Assignment|Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BERMUD Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEECHAM GROUP P.L.C.;REEL/FRAME:011495/0195 Effective date: 20010314 |
    2003-04-08| CC| Certificate of correction|
    2005-11-30| REMI| Maintenance fee reminder mailed|
    2006-05-15| LAPS| Lapse for failure to pay maintenance fees|
    2006-06-14| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2006-07-11| FP| Lapsed due to failure to pay maintenance fee|Effective date: 20060514 |
    优先权:
    申请号 | 申请日 | 专利标题
    GB838322199A|GB8322199D0|1983-08-18|1983-08-18|Pharmaceutical composition|
    GB8322199||1983-08-18||
    GB838325271A|GB8325271D0|1983-09-21|1983-09-21|Compounds|
    GB8325271||1983-09-21||
    GB848408322A|GB8408322D0|1984-03-30|1984-03-30|Compounds|
    GB8408322||1984-03-30||
    US64130084A| true| 1984-08-16|1984-08-16||
    GB8423833||1984-09-20||
    GB848423833A|GB8423833D0|1984-09-20|1984-09-20|Compounds|
    GB8510331||1985-04-23||
    GB858510331A|GB8510331D0|1985-04-23|1985-04-23|Compounds|
    GB858520618A|GB8520618D0|1985-08-16|1985-08-16|Compounds|
    GB8520618||1985-08-16||
    US77718885A| true| 1985-09-18|1985-09-18||
    US07/085,216|US5075445A|1983-08-18|1987-08-12|Guanine derivatives|
    US28539988A| true| 1988-12-15|1988-12-15||
    US60740390A| true| 1990-10-31|1990-10-31||
    US07/825,440|US5250688A|1984-09-20|1992-01-22|Purine derivatives|
    US91811192A| true| 1992-07-20|1992-07-20||
    US13208293A| true| 1993-10-05|1993-10-05||
    US08/258,167|US5684153A|1984-08-16|1994-06-10|Process for the preparation of purine derivatives|
    US08/884,731|US5886215A|1983-08-18|1997-06-30|2-acetoxymethyl-4-halo-butyl-1-yl acetates|
    US09/238,777|US6187922B1|1983-08-18|1999-01-27|Process for the preparation of purine derivatives|
    US09/734,051|US6388074B2|1983-08-18|2000-12-11|Process for the preparation of purine derivatives|US09/734,051| US6388074B2|1983-08-18|2000-12-11|Process for the preparation of purine derivatives|
    [返回顶部]